COO vs GMED
Cooper Companies (The) vs Globus Medical — AI-powered side-by-side comparison
COO
Cooper Companies (The)
66
Buy
VS
GMED
Globus Medical
70
Buy
| Metric | COO | GMED |
|---|
| AI Score |
66
|
70
|
| Price |
$74.25
|
$82.34
|
| P/E Ratio |
62.91×
|
20.74×
|
| ROE |
4.6%
|
11.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
64.4%
|
68.5%
|
| Debt / Equity |
0.30×
|
0.02×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
61.8
|
64.2
|
| Beta |
0.84
|
0.954
|
| Expected Upside |
+0.2%
|
+1.8%
|
AI Committee View
Current Innellis committee reasoning for COO versus GMED.
GMED leads by 4 points.
GMED scores 70/100 (Buy) versus COO at 66/100 (Buy).
COO Committee View
75% agreement
4 analysts
The primary driver is 4 consecutive earnings beats -- consistent execution. The main limiting factor is news sentiment is negative (-0.18 across 11 articles, 14d). The committee is constructive but not yet at full conviction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- News sentiment is negative (-0.18 across 11 articles, 14d) — News
GMED Committee View
100% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is 4 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- EPS growing 221.2% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Lower Highs / Lower Lows structure confirms bearish price action.